BIOMM

Institutional Presentation

October 2016

Life to Science

1

DISCLAIMER

This presentation and its contents are confidential and proprietary Biomm SA and its subsidiaries ( "Biomm"). By accepting this presentation, each recipient agree that you will not copy, reproduce or distribute to third parties the content of this presentation in whole or in part, without the prior written consent of Biomm.

Except as otherwise provided herein, this presentation contains information and opinions which refer only to the date hereof and are subject to change without notice.

The content of this presentation does not constitute a promise or representation regarding the future performance of the Company. Certain information and conclusions contained herein are based on projections, which Biomm believed to be reasonable, but have not been independently verified.

Several factors could cause future results, performance or Biomm´s events to be substantially different from those described in this presentation. Biomm, its directors, officers and employees shall not, under any circumstances, be liable to third parties (including investors) for investment decisions or acts or business carried out based on the information and statements contained in this presentation, or for indirect damage or profit loss. This presentation and its contents do not constitute basis for any contract or commitment whatsoever.

This presentation has been prepared for informational purposes only and should not be interpreted otherwise.

2

BIOMM HAS STRONG TIES WITH INSULIN PRODUCTION IN BRAZIL

1975 1979 1983 2000 2001

Establishment of Biobrás: Enzyme production using both animal and vegetable raw materials

Joint venture with North American Eli Lilly & Co: Production of insulin of animal origin in Brazil

Biobrás buys Eli Lilly’s share in the Joint Venture: Manufacture of highly purified insulin

First production patent for recombinant human insulin

Establishment of Biomm: Intellectual property, know-how, researchers and executives remain the same

3

WHAT MAKES BIOMM

THE BEST PARTNERIN BIOPHARMACEUTICALS IN BRAZIL?

4

Know-how, technology and patents in key global markets

Industrial plant already under construction

Experienced, specialized professionalsOrganizationStructure

Private Strategic and Government

funds

BIOMMIDEAL PARTNER IN

BIOPHARMACEUTICALS PRODUCTION IN BRAZIL

5

First class team

GUILHERME EMRICH

Chairman of the Board

Internationally recognized biotech entrepreneur

FRANCISCO FREITAS

LUCIANO VILELA

HERALDO MARCHEZINI

Operations Director

30+ years of experience; responsible for the plant project

Technology Director

Expert in the R&D field; author of several BIOMM´s patents

CEO

25 years of experience in the industry, former Sanofi´s CEO in Brazil

Executives with extensive experience and expertise are leading BIOMM:

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

DOUGLASLOPES

CFO & IR

5+ years experience in Management Consulting industryCOO / Marketing Director

CIRO MASSARI

Commercial Director

20+ of experience in the sector Sales and Marketing Director at Sanofi Brasil and Mexico

6

Organization StructureSupporting team covering most important areas in biotech project implementation:

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

LEGAL

TREASURY

CEO

CONTROLLER

ACCOUNTING

MARKETING SALES

HR

ENGINEERINGMAINTENAN-

CE AND PROCESSES

REGULATORYR&D

QUALITY CONTROL

QUALITY ASSURANCE

OSHACONSTRUCTION MGMT

BUSINESS DEVELOP.

MEDICAL MANAGER

COO CTO CFO COMMERCIAL DIRECTOR

7

An old relation with insulin in both production and technology development, and a number of patents granted in demanding countries like USA, Germany and Israel

The company preserved the intellectual capital, know-how and R&D team that made Biobrás an outstanding case of success.

Innovation TrackRecord

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

8

20patents in key global markets Over

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

9

Structure

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

Minas Gerais: Belo Horizonte: Administrative office Contagem: Distribution Center Montes Claros: R&D Lab Nova Lima: Industrial Plant

São Paulo: São Paulo: Commercial office

A modern 12 000 m2 biopharmaceutical plant is already being built in Nova Lima, MG and will be completed in 2016

10

Has positioned itself to the next wave of biologics

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

11

Pernambuco: Recife: Biologics Plant

Recently acquired real state area from Novartis for future portfolio expansion in biologics

Innovation Capital, by both private and public funds

The only Biopharmaceutical company listed in the BOVESPA stock exchange (BIOM3)

Funding

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

12

Solid capital structure that allow multiple sources of additional resources

Funding

WHAT MAKES BIOMM THE IDEAL PARTNER IN BIOPHARMACEUTICALS PRODUCTION IN BRAZIL?

FoundingPartners27,7%

14,0%

8,1%

21,7%

5,2%

EquityDistribution

Minorityand Float23,3%

PrivateEquity

13

Know-how, technology and patents in key global markets

Industrial plant already under construction

Experienced, specialized professionalsOrganizationStructure

Private Strategic and Government

funds

BIOMMIDEAL PARTNER IN

BIOPHARMACEUTICALS PRODUCTION IN BRAZIL

14

A SOLID REALITYA solid company, led by skilled professionals and investing heavily in one of the world’s most important industries

15